What stock options related to EVGN does Tarcic Gabi hold?

Tarcic Gabi holds stock options over 40,000 Ordinary Shares with an exercise price of $2.305 per share, expiring on November 20, 2034, as disclosed in the derivative securities section.

Evogene CDO buys 1,129 shares at $0.60 each

Q: What insider transaction did EVGN report for Tarcic Gabi on June 4, 2026?

Evogene reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share, in a transaction classified as a purchase in an open market or private transaction.

Q: How many Evogene (EVGN) shares does Tarcic Gabi own after this transaction?

After the June 4, 2026 transaction, Tarcic Gabi holds 1,129 Ordinary Shares of Evogene Ltd. directly, according to the filing’s post-transaction ownership figure.

Q: Did the June 4, 2026 EVGN Form 4 involve any stock option exercises?

No. The filing states that for the stock option holdings, there were no transactions and that the reporting person’s option holdings are provided for informational purposes only.

Q: How do Tarcic Gabi’s EVGN options vest?

The options vest over four years: 25% on the first anniversary of the November 20, 2024 grant date, and the remaining 75% vest in equal quarterly installments of 6.25% over the following twelve quarters.

Evogene Ltd. (EVGN) reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share in an open-market or private transaction.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share in an open-market or private transaction. Following this buy, Tarcic holds 1,129 Ordinary Shares directly and has stock options covering 40,000 Ordinary Shares at an exercise price of $2.305 per share, expiring November 20, 2034. The option position was unchanged and is disclosed for informational purposes, with vesting over four years from the November 20, 2024 grant date.

Insider Trade Summary

Net Buyer: 1,129 shares

Net Buy 2 txns

Insider Tarcic Gabi

Role Chief Development Officer

Bought 1,129 shs ($677.40)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	1,129	$0.60	$677.40
holding	Stock Option (right to buy) ^{F1, F2}	--	--	--

Holdings After Transaction: Ordinary Shares — 1,129 shares (Direct); Stock Option (right to buy) — 40,000 contracts (Direct)

Footnotes (2)

F1. The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.
F2. There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only.

Key Figures

Ordinary Shares purchased: 1,129 shares Purchase price per Ordinary Share: $0.60 per share Ordinary Shares held after transaction: 1,129 shares +5 more

8 metrics

Ordinary Shares purchased 1,129 shares Purchase on 2026-06-04 by Chief Development Officer Tarcic Gabi

Purchase price per Ordinary Share $0.60 per share Open-market or private transaction on 2026-06-04

Ordinary Shares held after transaction 1,129 shares Direct ownership following 2026-06-04 purchase

Underlying shares for stock options 40,000 Ordinary Shares Stock Option (right to buy) position held directly

Stock option exercise price $2.305 per share Exercise price for Stock Option (right to buy) on Ordinary Shares

Stock option expiration date 2034-11-20 Expiration of Stock Option (right to buy) over 40,000 Ordinary Shares

Initial option vesting 25% Vests on first anniversary of November 20, 2024 grant date

Ongoing quarterly vesting rate 6.25% per quarter Over twelve quarters after first anniversary of grant date

Key Terms

Stock Option (right to buy), Ordinary Shares, exercise price, vesting

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy) position with underlying Ordinary Shares"

Ordinary Shares financial

"security_title: Ordinary Shares; underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"conversion_or_exercise_price: 2.3050 per share for stock options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options reported in this row vest over a period of four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EVGN report for Tarcic Gabi on June 4, 2026?

Evogene reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share, in a transaction classified as a purchase in an open market or private transaction.

How many Evogene (EVGN) shares does Tarcic Gabi own after this transaction?

After the June 4, 2026 transaction, Tarcic Gabi holds 1,129 Ordinary Shares of Evogene Ltd. directly, according to the filing’s post-transaction ownership figure.

Did the June 4, 2026 EVGN Form 4 involve any stock option exercises?

No. The filing states that for the stock option holdings, there were no transactions and that the reporting person’s option holdings are provided for informational purposes only.

How do Tarcic Gabi’s EVGN options vest?

The options vest over four years: 25% on the first anniversary of the November 20, 2024 grant date, and the remaining 75% vest in equal quarterly installments of 6.25% over the following twelve quarters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/26/2026 - 04:02 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tarcic Gabi

(Last)

(First)

(Middle)

6 HASHIKMA ST.

(Street)

MEVASERET ZION

9071603

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol
[EVGN]

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/04/2026		P		1,129	A	$0.6	1,129	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)⁽¹⁾⁽²⁾	$2.305							⁽¹⁾	11/20/2034	Ordinary Shares	40,000		40,000	D

Explanation of Responses:

1. The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.

2. There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR